Etentamig for Newly Diagnosed Patients
Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Arms / Cohorts
Experimental:Etentamig + Daratumumab: Dose A
Accepting patients
Experimental:Phase 3: Daratumumab, Lenalidomide, and Dexamethasone (DRd)
Not yet accepting
Experimental:Etentamig + Daratumumab: Dose C
Accepting patients
Experimental:Etentamig + Daratumumab: Dose B
Accepting patients
Experimental:Phase 3: Etentamig + Daratumumab
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.